Is obesity a prognostic factor for acute myeloid leukemia outcome?

Hun Ju Lee; Andrea S. Licht; Andrew J. Hyland; Laurie A. Ford; Sheila N.J. Sait; Annemarie W. Block; Maurice Barcos; Maria R. Baer; Eunice S. Wang; Meir Wetzler

doi:10.1007/s00277-011-1319-8

Is obesity a prognostic factor for acute myeloid leukemia outcome?

Hun Ju Lee, Andrea S. Licht, Andrew J. Hyland, Laurie A. Ford, Sheila N.J. Sait, Annemarie W. Block, Maurice Barcos, Maria R. Baer, Eunice S. Wang, Meir Wetzler

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Obesity adversely affects outcome in pediatric acute lymphocytic leukemia and acute myeloid leukemia (AML). We asked if obesity, measured by body mass index (BMI), affected outcome in 329 adult AML patients treated with high-dose cytarabine and idarubicin-containing regimens administered according to actual body weight. Age ≥ 60, unfavorable karyotype, secondary AML, and positive smoking status had adverse impact on overall survival in a multivariate analysis, while BMI did not. We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction.

Original language	English (US)
Pages (from-to)	359-365
Number of pages	7
Journal	Annals of Hematology
Volume	91
Issue number	3
DOIs	https://doi.org/10.1007/s00277-011-1319-8
State	Published - Mar 2012
Externally published	Yes

Keywords

Acute myeloid leukemia
Body mass index
Obesity
Outcome

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-011-1319-8

Cite this

@article{081b49704a6e4441bbf935949f8f3455,

title = "Is obesity a prognostic factor for acute myeloid leukemia outcome?",

abstract = "Obesity adversely affects outcome in pediatric acute lymphocytic leukemia and acute myeloid leukemia (AML). We asked if obesity, measured by body mass index (BMI), affected outcome in 329 adult AML patients treated with high-dose cytarabine and idarubicin-containing regimens administered according to actual body weight. Age ≥ 60, unfavorable karyotype, secondary AML, and positive smoking status had adverse impact on overall survival in a multivariate analysis, while BMI did not. We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction.",

keywords = "Acute myeloid leukemia, Body mass index, Obesity, Outcome",

author = "Lee, {Hun Ju} and Licht, {Andrea S.} and Hyland, {Andrew J.} and Ford, {Laurie A.} and Sait, {Sheila N.J.} and Block, {Annemarie W.} and Maurice Barcos and Baer, {Maria R.} and Wang, {Eunice S.} and Meir Wetzler",

note = "Funding Information: Acknowledgements This work was supported partially by grants from the National Cancer Institute Grant CA16056 (HJL, ASL, AJH, LAF, SNJS, AWB, MB, MRB, ESW, MW), the Szefel Foundation, Roswell Park Cancer Institute (ESW), the Nancy C. Cully Endowment for Leukemia Research (MW), and the Heidi Leukemia Research Fund, Buffalo, NY (MW).",

year = "2012",

month = mar,

doi = "10.1007/s00277-011-1319-8",

language = "English (US)",

volume = "91",

pages = "359--365",

journal = "Annals of Hematology",

issn = "0939-5555",